Recurrent subcutaneous sweet’s disease in a myelofibrosis patient treated with ruxolitinib before allogeneic stem cell transplantation

Teppei Sakoda, Yoko Kanamitsu, Yasuo Mori, Kensuke Sasaki, Etsuko Yonemitsu, Konosuke Nagae, Goichi Yoshimoto, Kenjiro Kamezaki, Koji Kato, Katsuto Takenaka, Toshihiro Miyamoto, Masutaka Furue, Hiromi Iwasaki, Koichi Akashi

Research output: Contribution to journalArticle

3 Citations (Scopus)


Allogeneic hematopoietic stem cell transplantation (allo-SCT) has a curative potential for myelofibrosis (MF) patients; however, its association with a high therapy-related mortality (TRM) remains a big obstacle that needs to be overcome. Ruxolitinib (RUXO), a novel JAK1/2 inhibitor, can be used as a bridging therapy until allo-SCT can be performed to reduce TRM. We herein report a RUXO-treated MF patient who developed recurrent subcutaneous Sweet’s disease (SSD) that was successfully treated by the administration of systemic glucocorticoids. We performed allo-SCT as previously scheduled, resulting in a good clinical course without deterioration of SSD. RUXO administration, as well as MF itself, might therefore sometimes cause this rare non-infectious event.

Original languageEnglish
Pages (from-to)2481-2485
Number of pages5
JournalInternal Medicine
Issue number18
Publication statusPublished - Jan 1 2017


All Science Journal Classification (ASJC) codes

  • Internal Medicine

Cite this